L1CAM抗体;L1CAM Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11549(L1CAM Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11549(L1CAM Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

L1CAM (L1 cell adhesion molecule) is a transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily. Initially identified for its role in nervous system development, L1CAM mediates cell-cell adhesion, neuronal migration, axon guidance, and synaptic plasticity through interactions with extracellular matrix components and cell-surface receptors like integrins. Structurally, it comprises six Ig-like domains, five fibronectin type III repeats, a transmembrane region, and a cytoplasmic tail involved in intracellular signaling.

L1CAM antibodies are essential tools in research and diagnostics. In neuroscience, they help study neural development and disorders such as CRASH syndrome (a rare X-linked condition caused by L1CAM mutations). Beyond the nervous system, L1CAM is implicated in cancer progression, where its overexpression correlates with tumor invasion, metastasis, and poor prognosis in cancers like endometrial carcinoma, glioblastoma, and melanoma. Antibodies targeting L1CAM are used in immunohistochemistry, flow cytometry, and Western blotting to detect expression patterns and assess its role in disease mechanisms.

Therapeutically, L1CAM antibodies are explored for targeted cancer treatments, including antibody-drug conjugates or immune checkpoint inhibitors. However, challenges remain in ensuring specificity and minimizing off-target effects. Recent studies also investigate L1CAM's role in autoimmune diseases and tissue regeneration, broadening its clinical relevance. Overall, L1CAM antibodies bridge fundamental research and translational applications, highlighting their importance in understanding cellular adhesion pathways and developing precision therapies.